Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease

Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01696708

Acronym

PRO-MH2

Enrollment

Registered

2012-10-01

Start date

2012-12-06

Completion date

2015-11-30

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease

Brief summary

The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.

Interventions

OTHER31-Phosphorus RMN Spectroscopy

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* UHDRS \< 50 * Age \> 18 years * Ability to undergo MR scanning * Covered by french social security

Exclusion criteria

* Evidence of psychiatric disorder * Attendant neurological disorder * Contraindications to MRI (claustrophobia, metallic or material implants) * Severe head injury * Unable to understand the protocol * Pregnancy * Failure to give informed consent * Subjects with

Design outcomes

Primary

Measure	Time frame	Description
Ratio of Inorganic Phosphate (Pi) over phosphocreatine (PCr): Pi/PCr	2 years	31P-MRS allows quantification of high-energy phosphate metabolites such as phosphocreatine and inorganic phosphate

Secondary

Measure	Time frame	Description
Correlation between primary outcome measure and clinical parameters	2 years	Correlating a brain energy deficit with clinical parameters in Huntington patients such as the Unified Huntington's disease rating scale (UHDRS) and total functional capacity score (TFC).
Study of longitudinal changes in Pi/PCr ratio over time.	2 years	Patients will be retested after one month.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026